April 6, 2010 – SANUWAVE Health, Inc., (OTC BB: SNWV), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, announced that patient enrollment was completed in March in its dermaPACE™ Phase III pivotal, randomized, double-blinded, sham controlled, multicenter clinical trial comparing its Pulsed Acoustic Cellular Expression (PACE™) technology, utilizing the dermaPACE™ tissue regeneration device, to sham control for the treatment of diabetic foot ulcers (DFU).The primary study goal is to establish superiority in diabetic foot ulcer healing rates using the dermaPACE™ treatment compared to sham control, when both are combined with the current standard of care. The standard of care includes wet-to-dry dressings, the most widely used primary dressing material in the United States, and offloading with a walking boot... [PDF] SANUWAVE Health's Press Release -
